
Claims

1. Use of an IL-8 inhibitor in the manufacture of a medicament for the treatment and/or prevention of interstitial cystitis/painful bladder syndrome (IC/PBS) and/or over active bladder (OAB), wherein said IL-8 inhibitor is a CXCR1 inhibitor or a dual CXCR1 and CXCR2 inhibitor.

2. The use of claim 1, wherein said IC/PBS and/or over active bladder (OAB) is induced by anticancer therapy or radiotherapy to the pelvis.

3. The use of claim 1 or claim 2, wherein said IL8 inhibitor is selected from a small molecule, antibody or peptide.

4. The use of any one of claims 1 to 3, wherein said IL-8 inhibitor is a compound of formula (I)



(I)

or a pharmaceutically acceptable salt thereof,

wherein

R1 is hydrogen;

X is OH;


R2 is hydrogen or linear C_1-C_4 alkyl;

Y is a heteroatom selected from S, O and N;

Z is selected from linear or branched C_1-C_4 alkyl, linear or branched C_1-C_4 alkoxy, halo C_1-C_3 alkyl and halo C_1-C_3 alkoxy.

5. The use of any one of claims 1 to 4, wherein said IL-8 inhibitor is selected from (R,S)-2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino}phenyl)propanoic acid and (2S)-2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl] amino} phenyl) propanoic acid, preferably as sodium salt.

6. The use of any one of claims 1 to 3, wherein said IL-8 inhibitor is a compound of formula (II)



(II)

or a pharmaceutically acceptable salt thereof,

wherein

R' is hydrogen;

R is a residue of formula SO_2Ra wherein Ra is linear or branched C_1-C_4 alkyl or halo C_1-C_3 alkyl.


7. The use of any one of claims 1 to 3 and 6, wherein said IL-8 inhibitor is R(-)-2-[(4'-trifluoromethanesulfonyloxy)phenyl]-N-methanesulfonyl propionamide, preferably the sodium salt thereof.

8. Use of a pharmaceutical composition in the manufacture of a medicament for the treatment and/or prevention of interstitial cystitis/painful bladder syndrome (IC/PBS) and/or over active bladder (OAB) wherein the pharmaceutical composition comprises an IL-8 inhibitor wherein the IL-8 inhibitor is:

a) a CXCR1 inhibitor or a dual CXCR1 and CXCR2 inhibitor;

b) selected from a small molecule, antibody or peptide;

c) a compound of formula (I)



(I)

or a pharmaceutically acceptable salt thereof,

wherein

R1 is hydrogen;


X is OH;

R2 is hydrogen or linear C_1-C_4 alkyl;

Y is a heteroatom selected from S, O and N;

Z is selected from linear or branched C_1-C_4 alkyl, linear or branched C_1-C_4 alkoxy, halo C_1-C_3 alkyl and halo C_1-C_3 alkoxy; or

d) a compound of formula (II)



(II)

or a pharmaceutically acceptable salt thereof,

wherein

R' is hydrogen;

R is a residue of formula SO_2Ra wherein Ra is linear or branched C_1-C_4 alkyl or halo C_1-C_3 alkyl.

9. The useas claimed in claim 8, wherein said IL-8 inhibitor is selected from (R,S)-2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino}phenyl)propanoic acid and (2S)-2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl] amino} phenyl) propanoic acid, preferably as sodium salt, or wherein said IL-8 inhibitor is R(-)-2-[(4'-trifluoromethanesulfonyloxy)phenyl]-N-methanesulfonyl propionamide, preferably the sodium salt thereof.

10. The use as claimed in claim 8 or claim 9, further comprising at least one further pharmaceutically active compound.


11. A product or kit comprising:

A) a medicament for the treatment and/or prevention of interstitial cystitis/painful bladder syndrome (IC/PBS) and/or over active bladder (OAB) comprising an IL-8 inhibitor wherein the IL-8 inhibitor is:

a) a CXCR1 inhibitor or a dual CXCR1 and CXCR2 inhibitor;

b) selected from a small molecule, antibody or peptide;

c) a compound of formula (I)



(I)

or a pharmaceutically acceptable salt thereof,

wherein

R1 is hydrogen;


X is OH;

R2 is hydrogen or linear C_1-C_4 alkyl;

Y is a heteroatom selected from S, O and N;

Z is selected from linear or branched C_1-C_4 alkyl, linear or branched C_1-C_4 alkoxy, halo C_1-C_3 alkyl and halo C_1-C_3 alkoxy; or

d) a compound of formula (II)



(II)

or a pharmaceutically acceptable salt thereof,

wherein

R' is hydrogen;

R is a residue of formula SO_2Ra wherein Ra is linear or branched C_1-C_4 alkyl or halo C_1-C_3 alkyl,

or the medicamentaccording to claim 8 or claim 9, and

B) at least one further pharmaceutically active compound

A) and B) being two separate formulations for simultaneous, separate or sequential use,

wherein said IL-8 inhibitor is selected from (R,S)-2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino}phenyl)pro-panoic acid and (2S)-2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino}phenyl) pro-panoic acid, preferably as sodium salt, or wherein said IL-8 inhibitor is R(-)-2-[(4'-trifluoromethanesulfonyloxy)phenyl]-N-methanesulfonyl propionamide, preferably the sodium salt thereof.

12. The use as claimed in claim 10 or the product or kit as claimed in claim 11, wherein said further pharmaceutically active compound is an active compound useful for the prevention and treatment of IC/PBS, and/or OAB.

13. The use or the product or kit as claimed in claim 12, wherein said further pharmaceutically active compound is a TRPV1
antagonist.

14. The use as claimed in claim 10 or the product or kit as claimed in claim 11, wherein said further pharmaceutically active compound is a drug that induces, as an undesired effect, IC /PBS or OAB.

15. The use or the product or kit as claimed in claim 14, wherein said further pharmaceutically active compound is selected from cyclophosphamide, Bacillus Calmette-Guérin to be instilled directly into the bladder, mitomycin C, Adriamycin or tiaprofenic acid.